Utilization of nebulized 3% saline in infants hospitalized with bronchiolitis

The Journal of Pediatrics
Todd A FlorinSamir S Shah

Abstract

To describe utilization of 3% hypertonic saline (HTS) in hospitalized infants and to evaluate the association between HTS use and length of stay (LOS) in a real-world setting. This multicenter retrospective cohort study included infants≤12 months hospitalized with bronchiolitis between October 2008 and September 2011 using the Pediatric Health Information System. HTS use was categorized as trial, rescue, daily, or sporadic. Differences in LOS were compared after matching daily HTS recipients and nonrecipients on propensity score. There were 63,337 hospitalizations for bronchiolitis. HTS was used in 24 of 42 hospitals and 2.9% of all hospitalizations. HTS use increased from 0.4% of visits in 2008 to 9.2% of visits in 2011. There was substantial variation in HTS use across hospitals (range 0.1%-32.6%). When used, HTS was given daily during 60.6% of hospitalizations, sporadically in 10.4%, as a trial in 11.3%, and as a rescue in 17.7%. The propensity score-matched analysis of daily HTS recipients (n=953) vs nonrecipients (n=953) showed no difference in mean LOS (HTS 2.3 days vs nonrecipients 2.5 days; β-coefficient -0.04; 95% CI -0.15, 0.07; P=.5) or odds of staying longer than 1, 2, or 3 days. Daily HTS recipients had a 33% decre...Continue Reading

References

Oct 27, 1999·JAMA : the Journal of the American Medical Association·D K ShayL J Anderson
Sep 3, 2004·The Journal of Pediatrics·Caroline Breese Hall
Sep 24, 2004·Pharmacoepidemiology and Drug Safety·Sherry WeitzenVincent Mor
Oct 7, 2004·Pediatrics·Aileen B SedmanDarrell A Campbell
Apr 5, 2005·Pediatrics·Dimitri A ChristakisDanielle M Zerr
Oct 4, 2006·Pediatrics·UNKNOWN American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis
Jan 27, 2010·Pediatrics·Joseph J Zorc, Caroline Breese Hall
Jul 20, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Z LuoX Yang
Jul 22, 2010·The Journal of Pediatrics·Khalid Al-AnsariKhalid Ibrahim
Feb 26, 2011·Pharmacoepidemiology and Drug Safety·Daniel WestreichTil Stürmer
Oct 8, 2011·Pulmonary Pharmacology & Therapeutics·Ilke Ozahı IpekAbdulkadir Bozaykut
Oct 29, 2014·Pediatrics·Shawn L RalstonSinsi Hernandez-Cancio

❮ Previous
Next ❯

Citations

Mar 22, 2016·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Jeffrey Baron, Gladys El-Chaar
Feb 24, 2016·Expert Review of Respiratory Medicine·Silvia VandiniMarcello Lanari
May 14, 2016·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Christopher L Carroll The Northeast Pediatric Critical Care Research Consortium
Jun 18, 2017·Hospital Pediatrics·Steven L SheinBenjamin Gaston
Feb 6, 2019·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Steven L SheinAdrienne G Randolph

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.